NASDAQ: BCTXBriacell Therapeutics Corp Stock
$3.12-0.41 (-11.61%)
Updated Jun 13, 2025
BCTX Price
$3.12
Fair Value Price
$0.04
Market Cap
$11.57M
52 Week Low
$2.81
52 Week High
$29.40
P/E
-0.62x
P/B
3.59x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$11.78M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.9
Operating Cash Flow
-$22M
Beta
0.99
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
BCTX Overview
BriaCell Therapeutics Corp. develops immunotherapies for the treatment of cancer. Its lead candidate, Bria-IMT, is in Phase I/IIa clinical trials for the treatment of breast cancer. The company has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, personalized immunotherapy for advanced breast cancer, and BriaDx, a diagnostic test. BriaCell Therapeutics is headquartered in West Vancouver, Canada.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine BCTX's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
BCTX
Ranked#364 of 464
Ranked#364 of 464
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.18 | A | |
| $41.59 | A | |
| $23.53 | A |
Be the first to know about important BCTX news, forecast changes, insider trades & much more!
BCTX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BCTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BCTX ($3.12) is overvalued by 8,147.52% relative to our estimate of its Fair Value price of $0.04 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
BCTX ($3.12) is not significantly undervalued (8,147.52%) relative to our estimate of its Fair Value price of $0.04 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
BCTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more BCTX due diligence checks available for Premium users.
Valuation
BCTX fair value
Fair Value of BCTX stock based on Discounted Cash Flow (DCF)
Price
$3.12
Fair Value
$0.04
Overvalued by
8,147.52%
BCTX ($3.12) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BCTX ($3.12) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BCTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
BCTX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.62x
Industry
-108.97x
Market
31.36x
BCTX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.59x
Industry
4.66x
BCTX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BCTX's financial health
Profit margin
Revenue
$0.0
Net Income
-$6.3M
Profit Margin
0%
BCTX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$9.4M
Liabilities
$6.1M
Debt to equity
1.9
BCTX's short-term assets ($7.16M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BCTX's short-term assets ($7.16M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BCTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$5.9M
Investing
-$75.0k
Financing
$5.2M
BCTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BCTX vs Biotech Stocks
Briacell Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.